188 related articles for article (PubMed ID: 22591609)
1. Intracranial MEMS based temozolomide delivery in a 9L rat gliosarcoma model.
Masi BC; Tyler BM; Bow H; Wicks RT; Xue Y; Brem H; Langer R; Cima MJ
Biomaterials; 2012 Aug; 33(23):5768-75. PubMed ID: 22591609
[TBL] [Abstract][Full Text] [Related]
2. Improvement in the standard treatment for experimental glioma by fusing antibody Fc domain to endostatin.
Grossman R; Tyler B; Hwang L; Zadnik P; Lal B; Javaherian K; Brem H
J Neurosurg; 2011 Dec; 115(6):1139-46. PubMed ID: 21923243
[TBL] [Abstract][Full Text] [Related]
3. Combination of paclitaxel thermal gel depot with temozolomide and radiotherapy significantly prolongs survival in an experimental rodent glioma model.
Vellimana AK; Recinos VR; Hwang L; Fowers KD; Li KW; Zhang Y; Okonma S; Eberhart CG; Brem H; Tyler BM
J Neurooncol; 2013 Feb; 111(3):229-36. PubMed ID: 23224713
[TBL] [Abstract][Full Text] [Related]
4. Intracranial microcapsule drug delivery device for the treatment of an experimental gliosarcoma model.
Scott AW; Tyler BM; Masi BC; Upadhyay UM; Patta YR; Grossman R; Basaldella L; Langer RS; Brem H; Cima MJ
Biomaterials; 2011 Apr; 32(10):2532-9. PubMed ID: 21220172
[TBL] [Abstract][Full Text] [Related]
5. Combination of intracranial temozolomide with intracranial carmustine improves survival when compared with either treatment alone in a rodent glioma model.
Recinos VR; Tyler BM; Bekelis K; Sunshine SB; Vellimana A; Li KW; Brem H
Neurosurgery; 2010 Mar; 66(3):530-7; discussion 537. PubMed ID: 20173548
[TBL] [Abstract][Full Text] [Related]
6. Captopril inhibits Matrix Metalloproteinase-2 and extends survival as a temozolomide adjuvant in an intracranial gliosarcoma model.
Pinheiro L; Perdomo-Pantoja A; Casaos J; Huq S; Paldor I; Vigilar V; Mangraviti A; Wang Y; Witham TF; Brem H; Tyler B
Clin Neurol Neurosurg; 2021 Aug; 207():106771. PubMed ID: 34198223
[TBL] [Abstract][Full Text] [Related]
7. Local delivery of angiogenesis-inhibitor minocycline combined with radiotherapy and oral temozolomide chemotherapy in 9L glioma.
Bow H; Hwang LS; Schildhaus N; Xing J; Murray L; Salditch Q; Ye X; Zhang Y; Weingart J; Brem H; Tyler B
J Neurosurg; 2014 Mar; 120(3):662-9. PubMed ID: 24359008
[TBL] [Abstract][Full Text] [Related]
8. The effects of temozolomide delivered by prolonged intracerebral microinfusion against the rat brainstem GBM allograft model.
Yoshimura J; Siu IM; Thomale UW; Jallo GI
Childs Nerv Syst; 2012 May; 28(5):707-13. PubMed ID: 22391876
[TBL] [Abstract][Full Text] [Related]
9. Local delivery of temozolomide by biodegradable polymers is superior to oral administration in a rodent glioma model.
Brem S; Tyler B; Li K; Pradilla G; Legnani F; Caplan J; Brem H
Cancer Chemother Pharmacol; 2007 Oct; 60(5):643-50. PubMed ID: 17256133
[TBL] [Abstract][Full Text] [Related]
10. Biodegradable wafers releasing Temozolomide and Carmustine for the treatment of brain cancer.
Shapira-Furman T; Serra R; Gorelick N; Doglioli M; Tagliaferri V; Cecia A; Peters M; Kumar A; Rottenberg Y; Langer R; Brem H; Tyler B; Domb AJ
J Control Release; 2019 Feb; 295():93-101. PubMed ID: 30605703
[TBL] [Abstract][Full Text] [Related]
11. Antitumor effect of fibrin glue containing temozolomide against malignant glioma.
Anai S; Hide T; Takezaki T; Kuroda J; Shinojima N; Makino K; Nakamura H; Yano S; Kuratsu J
Cancer Sci; 2014 May; 105(5):583-91. PubMed ID: 24673719
[TBL] [Abstract][Full Text] [Related]
12. Clinical outcome of patients with primary gliosarcoma treated with concomitant and adjuvant temozolomide: A single institutional analysis of 27 cases.
Rath GK; Sharma DN; Mallick S; Gandhi AK; Joshi NP; Haresh KP; Gupta S; Julka PK
Indian J Cancer; 2015; 52(4):599-603. PubMed ID: 26960490
[TBL] [Abstract][Full Text] [Related]
13. Local delivery of slow-releasing temozolomide microspheres inhibits intracranial xenograft glioma growth.
Dong J; Zhou G; Tang D; Chen Y; Cui B; Dai X; Zhang J; Lan Q; Huang Q
J Cancer Res Clin Oncol; 2012 Dec; 138(12):2079-84. PubMed ID: 22825126
[TBL] [Abstract][Full Text] [Related]
14. Liposomal temozolomide drug delivery using convection enhanced delivery.
Nordling-David MM; Yaffe R; Guez D; Meirow H; Last D; Grad E; Salomon S; Sharabi S; Levi-Kalisman Y; Golomb G; Mardor Y
J Control Release; 2017 Sep; 261():138-146. PubMed ID: 28666727
[TBL] [Abstract][Full Text] [Related]
15. Delivery of temozolomide to the tumor bed via biodegradable gel matrices in a novel model of intracranial glioma with resection.
Akbar U; Jones T; Winestone J; Michael M; Shukla A; Sun Y; Duntsch C
J Neurooncol; 2009 Sep; 94(2):203-12. PubMed ID: 19337695
[TBL] [Abstract][Full Text] [Related]
16. In vivo delivery of BCNU from a MEMS device to a tumor model.
Li Y; Ho Duc HL; Tyler B; Williams T; Tupper M; Langer R; Brem H; Cima MJ
J Control Release; 2005 Aug; 106(1-2):138-45. PubMed ID: 16167384
[TBL] [Abstract][Full Text] [Related]
17. Local delivery of cancer-cell glycolytic inhibitors in high-grade glioma.
Wicks RT; Azadi J; Mangraviti A; Zhang I; Hwang L; Joshi A; Bow H; Hutt-Cabezas M; Martin KL; Rudek MA; Zhao M; Brem H; Tyler BM
Neuro Oncol; 2015 Jan; 17(1):70-80. PubMed ID: 25053853
[TBL] [Abstract][Full Text] [Related]
18. Temozolomide use in adult patients with gliosarcoma: an evolving clinical practice.
Walker GV; Gilbert MR; Prabhu SS; Brown PD; McAleer MF
J Neurooncol; 2013 Mar; 112(1):83-9. PubMed ID: 23266723
[TBL] [Abstract][Full Text] [Related]
19. Optimizing interstitial delivery of BCNU from controlled release polymers for the treatment of brain tumors.
Sipos EP; Tyler B; Piantadosi S; Burger PC; Brem H
Cancer Chemother Pharmacol; 1997; 39(5):383-9. PubMed ID: 9054951
[TBL] [Abstract][Full Text] [Related]
20. The effectiveness and cost-effectiveness of carmustine implants and temozolomide for the treatment of newly diagnosed high-grade glioma: a systematic review and economic evaluation.
Garside R; Pitt M; Anderson R; Rogers G; Dyer M; Mealing S; Somerville M; Price A; Stein K
Health Technol Assess; 2007 Nov; 11(45):iii-iv, ix-221. PubMed ID: 17999840
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
